Alios BioPharma has signed an exclusive worldwide licensing agreement with Versitech to develop, manufacture and market medication to combat influenza viruses.

In addition, the companies have also entered into two other influenza-related, non-exclusive licence agreements and a sponsored research agreement.

Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alios BioPharma president and CEO Lawrence Blatt said that the compounds and technology derived from the deal will provide key therapeutic options to help improve patients infected from influenza virus.

See Also: